Residual Risk of Cardiovascular Disease Among Patients Treated According to Guidelines for Secondary Prevention

被引：0
|
作者：
Nichols, Gregory A.
Pedula, Kathryn L.
Wang, Fang Q.
机构：
[1] Kaiser Permanente Ctr Hlth Res, Portland, OR USA
[2] GlaxoSmithKline Inc, King Of Prussia, PA USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2009年 / 53卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A380 / A380
页数：1
相关论文
共 50 条
  • [11] Physical Activity and Exercise for Secondary Prevention among Patients with Cardiovascular Disease
    Darden D.
    Richardson C.
    Jackson E.A.
    Current Cardiovascular Risk Reports, 2013, 7 (6) : 411 - 416
  • [12] New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
    Atar, Dan
    Jukema, J. Wouter
    Molemans, Bart
    Taub, Pam R.
    Goto, Shinya
    Mach, Francois
    CerezoOlmos, Cesar
    Underberg, James
    Keech, Anthony
    Tokgozoglu, Lale
    Bonaca, Marc P.
    ATHEROSCLEROSIS, 2021, 319 : 51 - 61
  • [13] Prevention of ischaemic events in patients with peripheral arterial disease according to the European guidelines on cardiovascular disease prevention in clinical practice
    Blinc, A.
    Kozak, M.
    Sabovic, M.
    Bozic, M.
    Stegnar, M.
    Poredos, P.
    Kravos, A.
    Zagar, B. Barbic
    Perme, M. Pohar
    Stare, J.
    EUROPEAN HEART JOURNAL, 2009, 30 : 509 - 510
  • [14] Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece
    Fragoulakis, Vassilis
    Kourlaba, Georgia
    Maniadakis, Nikolaos
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 : 135 - 143
  • [15] INCIDENCE OF CARDIOVASCULAR EVENTS AMONG SECONDARY PREVENTION PATIENTS TREATED WITH STATINS OR EZETIMIBE IN JAPAN
    Nagar, S. P.
    Fox, K. M.
    Rane, P. P.
    Beaubrun, A.
    Qian, Y.
    Inomata, H.
    Davis, K. L.
    Meyers, J.
    Kajinami, K.
    VALUE IN HEALTH, 2017, 20 (05) : A261 - A261
  • [16] The Effects of Secondary Cardiovascular Prevention on Cancer Risk in Patients With Manifest Vascular Disease
    van Kruijsdijk, Rob C. M.
    van der Graaf, Yolanda
    Algra, Ale
    de Borst, Gert Jan
    Cramer, Maarten J.
    Siersema, Peter D.
    Peeters, Petra H. M.
    Visseren, Frank L. J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (23) : 2588 - 2589
  • [17] Role of diabetes in residual risk among statin treated patients with prior cardiovascular events
    Weinrauch, Larry
    D'Elia, John A.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (03)
  • [18] RISK STRATIFICATION WITH THE TIMI RISK SCORE FOR SECONDARY PREVENTION AMONG PATIENTS WITH DIABETES AND ELEVATED CARDIOVASCULAR RISK
    Bergmark, Brian
    Bhatt, Deepak
    Bohula, Erin
    Morrow, David
    Steg, Philippe
    Mosenzon, Ofri
    Raz, Itamar
    Braunwald, Eugene
    Scirica, Benjamin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 8 - 8
  • [19] GUIDELINES Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance
    Rabar, Silvia
    Harker, Martin
    O'Flynn, Norma
    Wierzbicki, Anthony S.
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [20] Impact of 2021 ESC Guidelines for Cardiovascular Disease Prevention on Hypertensive Patients Risk: Secondary Analysis of Save Your Heart Study
    Del Pinto, Rita
    Giua, Corrado
    Keber, Enrico
    Grippa, Eleonora
    Tilotta, Marco
    Ferri, Claudio
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2023, 30 (02) : 167 - 173
12345